Critical appraisal, assignment of a grade for methodological quality of individual studies, and subsequent grading a body of evidence addressing a specific question are essential activities of conducting comparative effectiveness reviews.
Comments on the draft handbook from from Bryan Luce, of United BioSource Corp.
Remember, know WHAT you are measuring and WHY you are measuring it. (Source: InPharm, July 20, 2011)
This article summarizes findings of a report funded by The Commonwealth Fund Commission on a High Performance Health System, including 15 federal policy options and their potential for lowering health spending are examined. (Source: Brian Ahier, Health IT & Healthcare Reform, Nov 21, 2009)
Welcome to the CEA Registry Blog by the Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA. We have developed this blog to encourage interactivity among our users by allowing readers to post comments and questions about the Registry. The forum of this blog ranges from posting brief online updates to more in-depth content, enabling our users to be in-the-know about new developments and resources. We invite all comments and suggestions.
Overview of Risk Evaluation and Mitigation Strategies (REMS) and Risk Management Plans (RMPs) in US and Europe.
NPC asked the panelists for their insights on the challenges of developing and using evidence
Consumer Reports publication "Best Buy Drugs (or Best Drugs For Less)" which rates 200 Rx and OTC drugs on efficacy and cost, using an "unbiased review of the best scientific evidence available". They work closely with experts at Drug Effectiveness Review Project, part of the Oregon Health and Science University in Portland.
Information on the threshold values used in CHOICE analyses for the relative CE of an intervention in current international dollars of 2000 for 14 countries. Following the recommendations of the Commission on Macroeconomics and Health, CHOICE uses gross domestic product (GDP) as a readily available indicator to derive the following three categories of cost-effectiveness: Highly cost-effective (less than GDP per capita); Cost-effective (between one and three times GDP per capita); and Not cost-effective (more than three times GDP per capita)
A RAND Corp. study suggests that the estimated the savings from electronic medical records would be about $77 billion a year. But, a new Harvard study suggests all of these claims are simply wrong. Health “information technology,” the research concluded, has yielded neither substantial efficiencies nor any real savings at the U.S. hospitals that today use various forms of it.(Source: Emily Badger, Miller-McCune, Nov. 23, 2009)
Provides data on regional costs and spending for healthcare. Website provides access to all Atlas reports and publications, as well as interactive tools to allow visitors to view specific regions and perform their own comparisons and analyses.
Wikipedia listing. Needs input. Also help create a Wikipedia "health outcomes" listing. There isn't one! Email email@example.com if you want to work together to do this.
Health economics is a sub-discipline of economics and studies the allocation of scarce resources among alternative healthcare programs or strategies for the promotion, maintenance and improvement of health. Health economics studies how healthcare and health-related services, their costs and benefits, and health itself are distributed among individuals and groups in society. Health economics is concerned with the formal analysis of direct and indirect costs and benefits that are a consequence of a health care intervention, program or strategy. The science of health economics has significantly progressed in recent years. Although a lot of disagreement among health economists existed in the early nineties, over the recent years more consensus on methodology has been reached. This development resulted in a standardised approach, allowing valid comparisons of studies in different fields of health care and across countries. The main study types used in economic evaluation are cost-effectiveness (CEA) and cost-utility analysis (CUA) in which the incremental net costs of a programme are related to the health benefits.
Emphasis on understanding the comparative effectiveness of health care interventions has increased attention on the applicability of research. As a result, systematic reviews aiming to inform clinical practice have expanded beyond randomized controlled trials, which have limited generalizability, to include nonrandomized studies
Listing of hundreds of recruiters and headhunters with names, firms, postal, phone, fax, web and e-mail addresses. Time-saver for job hunters.
National Academic Mailing List Service, known as 'JISCMail', is a service designed specifically for the further and higher education and research communities and is one of a number of services provided by JISC Advance therefore making it the foremost strategic collaboration tool within the academic community.
Software tool developed to identify the disease burden of any population. It predicts the incidence of disease for any population of members, benchmarks the predicted incidence against national standards, and identifies outliers from a disease frequency and a cost perspective.
Pharmaceutical companies spent $57.5 billion on pharmaceutical promotion in the United States in 2004. The industry claims that promotion provides scientific and educational information to physicians. While some evidence indicates that promotion may adversely influence prescribing, physicians hold a wide range of views about pharmaceutical promotion.
The report recommends focusing more on learning outcomes, incorporating more clinical experiences early in medical education, and offering more opportunities for medical students to train in teams with nursing and other health-care students. The report also calls for a more individualized approach to medical education and training.
On line daily news with special areas devoted to medical, nursing, pharmaceutical companies, consumers, etc.
Performs customized calculations of the value of new drugs, medical devices and other therapeutic interventions. The Model links cost and utilization data from large patient care databases to published clinical data specific to new drugs, classes of drugs, diagnostics, medical technologies, or a combination of drugs and technologies used to treat a specific disease.
Very nice compilation of relevant resources.
The Code of Federal Regulations (CFR) is a codification of the general and permanent rules published in the Federal Register by the Executive departments and agencies of the Federal Government.
Good Reprint Practices for the Distribution of Medical Journal Articles and Medical or Scientific Reference Publications on Unapproved New Uses of Approved Drugs and Approved or Cleared Medical Devices
A popular pharma BLOG that is read by a lot of people again and again published content from such studies on Avandia and even went as far as to interview a former FDA official causing a lot of damage to the brand at a time when a scientific approach was needed.